RxDoctor Payments Data

Keval Shah, DO

Gastroenterology · Oxnard, CANPI 1093035917

Payments from drug & device makers

$252,800in general payments, 2019–2025

Across 705 payments — averaging $358.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$239K
  • AbbVie$5K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Johnson & Johnson$887
  • QOL Medical, LLC$736
  • Ardelyx, Inc.$635
  • plus $5K from 34 others

What the payments were for

  • Consulting fees$5504%
  • Speaking & faculty fees$4003%
  • Food & beverage$12,21291%
  • Education$2172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$252,800 in reported general payments places this provider in the 90th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$340,622
Medicare patients
616
Services billed
2,573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab15$185,665
CreonLipase/Protease/Amylase33$101,333
ZenpepLipase/Protease/Amylase16$57,348
LinzessLinaclotide40$44,477
XifaxanRifaximin13$39,225
Mesalamine18$7,267
CholestyramineCholestyramine (With Sugar)16$2,114
Omeprazole237$2,076
Pantoprazole Sodium56$675
Sulfasalazine16$537
Ondansetron Hcl14$246
Esomeprazole Magnesium11$223
Dicyclomine Hcl13$195
Famotidine22$187
Spironolactone12$176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$5,074$145,81073 claims
Aimmune Therapeutics, Inc.Zenpep$399$57,34816 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,199$39,22513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Oxnard

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →